The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077 · cited 1×
“In the brain, cannabinoids activate the type 1 cannabinoid (CB1) receptor, which is densely expressed in a number of regions related to the modulation of fear and anxiety (Mackie, 2005; Pacher et al., 2006).”
BackgroundThe molecular logic of endocannabinoid signalling
Piomelli, D. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1247 · Cited by 1,957 · cited 1×
“An alternative approach to the direct activation of CB1 receptors is the enhancement of the availability of the endogenous ligands, referred to as endocannabinoids (eCBs), of which anandamide and 2-arachidonoylglycerol (2-AG) are the mostly investigated (Piomelli, 2003).”
BackgroundThe endogenous cannabinoid system controls extinction of aversive memories
Marsicano, G., Wotjak, C. T., Azad, S. C., Bisogno, T., Rammes, G., Cascio, M. G., Hermann, H., Tang, J., Hofmann, C., Zieglgänsberger, W., et al. (2002) · Nature · doi:10.1038/nature00839 · Cited by 1,728 · cited 4×
“Indeed, increased levels of eCBs were observed during aversive stimuli in key regions related to fear and anxiety responses, where this system may act on-demand to oppose the impact of stress (Marsicano et al., 2002).”
BackgroundInfluentialSelf-citationBourin, M., & Hascoët, M. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01274-3 · Cited by 1,427
Cravatt, B. F., Demarest, K., Patricelli, M. P., Bracey, M. H., Giang, D. K., Martin, B. R., & Lichtman, A. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161191698 · Cited by 1,310
Modulation of anxiety through blockade of anandamide hydrolysis
Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Rana, G. L., Calignano, A., et al. (2003) · Nature Medicine · doi:10.1038/nm803 · Cited by 1,293 · cited 8×
“Consistent with our study, Kathuria et al. (2003) also showed that rimonabant blocked the anxiolytic effect induced by pharmacological inhibition of FAAH in rats, also pointing to an involvement of CB1 receptors in the anxiolytic.”
BackgroundMethodResultInfluentialEthological and temporal analyses of anxiety-like behavior: The elevated plus-maze model 20 years on
Carobrez, A. P., & Bertoglio, L. J. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.04.017 · Cited by 1,005
The neurobiology and control of anxious states
Millan, M. J. (2003) · Progress in Neurobiology · doi:10.1016/s0301-0082(03)00087-x · Cited by 965
Marsicano, G., & Lutz, B. (1999) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1999.00847.x · Cited by 937
Self-citationHall, W., & Solowij, N. (1998) · The Lancet · doi:10.1016/s0140-6736(98)05021-1 · Cited by 772
Cited by
Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials
Christensen, R., Kristensen, P. K., Bartels, E. M., Bliddal, H., & Astrup, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61721-8 · Cited by 1,097
Targeting the endocannabinoid system: to enhance or reduce?
Di Marzo, V. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2553 · Cited by 798
Enzymatic pathways that regulate endocannabinoid signaling in the nervous system
Ahn, K., McKinney, M. K., & Cravatt, B. F. (2008) · Chemical Reviews · doi:10.1021/cr0782067 · Cited by 529
The endocannabinoid system in guarding against fear, anxiety and stress
Lutz, B., Marsicano, G., Maldonado, R., & Hillard, C. J. (2015) · Nature reviews. Neuroscience · doi:10.1038/nrn4036 · Cited by 506
Self-citationNew approaches and challenges to targeting the endocannabinoid system
Di Marzo, V. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.115 · Cited by 480
Discovery and Characterization of a Highly Selective FAAH Inhibitor that Reduces Inflammatory Pain
Ahn, K., Johnson, D. S., Mileni, M., Beidler, D., Long, J. Z., McKinney, M. K., Weerapana, E., Sadagopan, N., Liimatta, M., Smith, S. E., et al. (2009) · Chemistry & Biology · doi:10.1016/j.chembiol.2009.02.013 · Cited by 439
Chemical Probes of Endocannabinoid Metabolism
Blankman, J. L., & Cravatt, B. F. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.006387 · Cited by 327
Mansur, R. B., Brietzke, E., & McIntyre, R. S. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.12.017 · Cited by 322
Jennings, E. M., Okine, B. N., Roche, M., & Finn, D. P. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.06.003 · Cited by 318
FAAH genetic variation enhances fronto-amygdala function in mouse and human
Dincheva, I., Drysdale, A. T., Hartley, C. A., Johnson, D. C., Jing, D., King, E. C., Ra, S., Gray, J. M., Yang, R., DeGruccio, A. M., et al. (2015) · Nature Communications · doi:10.1038/ncomms7395 · Cited by 289
The neurobiology of individual differences in complex behavioral traits
Hariri, A. R. (2009) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.051508.135335 · Cited by 273
Differential role of anandamide and 2-arachidonoylglycerol in memory and anxiety-like responses
Busquets-Garcia, A., Puighermanal, E., Pastor, A., de la Torre, R., Maldonado, R., & Ozaita, A. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.04.022 · Cited by 273
Moreira, F. A., Grieb, M., & Lutz, B. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.09.003 · Cited by 272
Self-citationHill, M. N., Kumar, S. A., Filipski, S. B., Iverson, M., Stuhr, K. L., Keith, J. M., Cravatt, B. F., Hillard, C. J., Chattarji, S., & McEwen, B. S. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.90 · Cited by 222
Effects of endocannabinoid system modulation on cognitive and emotional behavior
Zanettini, C. (2011) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2011.00057 · Cited by 214
Micale, V., Cristino, L., Tamburella, A., Petrosino, S., Leggio, G. M., Drago, F., & Di Marzo, V. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.98 · Cited by 207
Sciolino, N. R., Zhou, W., & Hohmann, A. G. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2011.04.010 · Cited by 179
“Our results, along with those of others (6, 13, 15, 24, 28, 60), suggest that inhibition of endocannabinoid-degrading enzymes prolongs endocannabinoid signaling to produce monophasic, treatment-like effects on anxiety.”
BackgroundResultKinsey, S. G., O'Neal, S. T., Long, J. Z., Cravatt, B. F., & Lichtman, A. H. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.12.002 · Cited by 170
Anxiety, stress, and fear response in mice with reduced endocannabinoid levels
Jenniches, I., Ternes, S., Albayram, O., Otte, D. M., Bach, K., Bindila, L., Michel, K., Lutz, B., Bilkei-Gorzo, A., & Zimmer, A. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.03.033 · Cited by 169
Self-citationHaller, J., Barna, I., Barsvari, B., Gyimesi Pelczer, K., Yasar, S., Panlilio, L. V., & Goldberg, S. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1494-7 · Cited by 159
Bluett, R. J., Gamble-George, J. C., Hermanson, D. J., Hartley, N. D., Marnett, L. J., & Patel, S. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.53 · Cited by 157
Shonesy, B. C., Bluett, R. J., Ramikie, T. S., Báldi, R., Hermanson, D. J., Kingsley, P. J., Marnett, L. J., Winder, D. G., Colbran, R. J., & Patel, S. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.11.001 · Cited by 155
Natural selection shaped the rise and fall of passenger pigeon genomic diversity
Murray, G. G. R., Soares, A. E. R., Novak, B. J., Schaefer, N. K., Cahill, J. A., Baker, A. J., Demboski, J. R., Doll, A., Da Fonseca, R. R., Fulton, T. L., et al. (2017) · Science · doi:10.1126/science.aao0960 · Cited by 132
Substrate-selective COX-2 inhibition decreases anxiety via endocannabinoid activation
Hermanson, D. J., Hartley, N. D., Gamble-George, J., Brown, N., Shonesy, B. C., Kingsley, P. J., Colbran, R. J., Reese, J., Marnett, L. J., & Patel, S. (2013) · Nature Neuroscience · doi:10.1038/nn.3480 · Cited by 126
“Since the anxiolytic effects of FAAH inhibition are mediated via AEA acting on CB 1 cannabinoid receptors 22,40 , we next tested the role of CB 1 receptors in the anxiolytic-like behavioral effects of LM-4131 in the open field arena.”
Wei, D., Dinh, D., Lee, D., Li, D., Anguren, A., Moreno-Sanz, G., Gall, C. M., & Piomelli, D. (2016) · Cannabis and Cannabinoid Research · doi:10.1089/can.2015.0008 · Cited by 122
Godlewski, G., Alapafuja, S. O., Bátkai, S., Nikas, S. P., Cinar, R., Offertáler, L., Osei-Hyiaman, D., Liu, J., Mukhopadhyay, B., Harvey-White, J., et al. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.08.013 · Cited by 95
Endocannabinoid-mediated synaptic plasticity and addiction-related behavior
Sidhpura, N., & Parsons, L. H. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.05.034 · Cited by 92
Brusberg, M., Arvidsson, S., Kang, D., Larsson, H., Lindström, E., & Martinez, V. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5166-08.2009 · Cited by 88
Chapter 5 The Endocannabinoid System as A Target for Novel Anxiolytic and Antidepressant Drugs
Gaetani, S., Dipasquale, P., Romano, A., Righetti, L., Cassano, T., Piomelli, D., & Cuomo, V. (2009) · International Review of Neurobiology · doi:10.1016/s0074-7742(09)85005-8 · Cited by 83
“In accordance with the observation reported from pharmacological studies, FAAH / mice exhibit reduced anxiety-like behavior in two experimental models, the elevated plus maze and the light–dark test (Moreira et al., 2008).”
BackgroundResultInfluentialRossi, S., De Chiara, V., Musella, A., Sacchetti, L., Cantarella, C., Castelli, M., Cavasinni, F., Motta, C., Studer, V., Bernardi, G., et al. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.064196 · Cited by 82
“FAAH( / ) mice (Cravatt et al., 2001; Maccarrone et al., 2008) display reduced anxious behavior (Moreira et al., 2008), and thus we tested whether the activity of stresssensitive CB1Rs(GABA) was preserved after social defeat stress in these mutants, as seen in response to intraperito- neal URB597.”
BackgroundInfluentialCassano, T., Gaetani, S., Macheda, T., Laconca, L., Romano, A., Morgese, M. G., Cimmino, C. S., Chiarotti, F., Bambico, F. R., Gobbi, G., et al. (2011) · Psychopharmacology · doi:10.1007/s00213-010-2051-0 · Cited by 72
“Differences in the experimental contexts have been proposed as key factors determining such discrepancies ( Moreira et al. 2008 ).”
InfluentialModulation of defensive behavior by transient receptor potential vanilloid type-1 (TRPV1) channels
Aguiar, D. C., Moreira, F. A., Terzian, A. L., Fogaça, M. V., Lisboa, S. F., Wotjak, C. T., & Guimaraes, F. S. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.03.026 · Cited by 57
Self-citationKlugmann, M., Goepfrich, A., Friemel, C. M., & Schneider, M. (2011) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2011.00037 · Cited by 49
Markey, L., Hooper, A., Melon, L. C., Baglot, S., Hill, M. N., Maguire, J., & Kumamoto, C. A. (2020) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2020.104808 · Cited by 45
Almeida-Santos, A. F., Gobira, P. H., Rosa, L. C., Guimaraes, F. S., Moreira, F. A., & Aguiar, D. C. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.05.027 · Cited by 41
Metadata
- Authors
- Moreira, F. A., Kaiser, N., Monory, K., & Lutz, B.
- Venue
- Neuropharmacology
- Publisher
- Elsevier BV
- Published
- 2008-01
- Volume
- 54
- Issue
- 1
- Pages
- 141-150
- ISSN
- 0028-3908 (ISSN-L)
- OpenAlex
- W2018723047
- Cited by
- 281
- References
- 45
- FWCI
- 12.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.